Manufacturer of all European product (including that shipped from India):
Bayer AG
Kaiser-Wilhelm-Allee
51368 Leverkusen
Germany
Information about Kerendia (Finerenone)
Kerendia (finerenone) is a selective mineralocorticoid receptor antagonist (MRA) used primarily for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes. It works by blocking the effects of aldosterone, which can contribute to kidney damage.
Product Highlights
The treatment of chronic kidney disease in adults with type 2 diabetes to slow the progression of kidney disease and reduce the risk of cardiovascular events.
Key Ingredient
Finerenone
Key Benefits
Helps to slow the progression of CKD in patients with type 2 diabetes.
Reduces the risk of cardiovascular events, such as heart attack or stroke, in at-risk patients.
The selective action may lead to a lower incidence of hyperkalemia (elevated potassium levels) compared to traditional MRAs.
Direction of Use
The recommended starting dose is typically 10 mg once daily, which may be adjusted based on patient response and tolerance.
Can be taken with or without food; swallow tablets whole.
Regular monitoring of kidney function and potassium levels is essential during treatment.
Recommended Starting Dosage
eGFR (mL/min/1.73m2 )
Starting Dose
≥ 60
20 mg once daily
≥ 25 to < 60
10 mg once daily
< 25
Not Recommended
Safety Concerns
Risk of elevated potassium levels; monitoring is required.
May affect renal function; adjustments may be necessary based on lab results.
Potential for low blood pressure, especially in patients on multiple antihypertensive medications.
Avoid Kerendia (Finerenone) If
History of allergy to finerenone or any of its ingredients.
Avoid use in patients with severe renal impairment (eGFR < 25 mL/min).
Should not be used in patients with significant hyperkalemia (potassium > 5.5 mEq/L) at baseline.
